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Evidence regarding the effectiveness of health technologies
can be distorted via numerous mechanisms, including
publication bias, methodological errors, over-interpretation
of findings and fraud. In recent years, popular science
writers have brought these issues to the fore, resulting in
popular movements to improve the credibility of science.
One particularly effective campaign has been that of the
AllTrials movement, which focuses on the pre-registration
and reporting of all clinical trials [1]. Many of the concerns
that led to this campaign can be observed in the context of
decision modelling.
In 2010, researchers called for the creation of a collab-
orative organisation to oversee a registry of decision
models [2]. The concept was not realised. In recent years,
the landscape of academic publishing and collaboration has
changed dramatically. In this editorial, we restate the call
for a model registry and recommend actionable steps for its
introduction.
1 The Problem
Compared with clinical trial analysis, the potential for
distortion in model-based economic evaluation—inten-
tional or otherwise—is considerable [3]. There are at least
four reasons for this. First, the analyst is not constrained to
analysing those parameters elicited within a single primary
research study; there are more avenues by which to influ-
ence the results via parameter selection, particularly in
relation to costs [4]. Second, it behoves the analyst to
identify (and perhaps even define) the perspective for the
analysis; the decision about which parameters are relevant
can be subjective [5]. Third, models often adopt a lifetime
horizon that requires extrapolation from studies with short
follow-up periods, meaning that sources of bias may be
amplified to constitute a major influence on results [6].
Moreover, the selected length of the time horizon can have
a major impact. Finally, models invariably require
assumptions due to the complex dynamics of the real world
that must be condensed, and any of these might influence
the results.
The primary purpose of clinical trial registries, at least in
their conception, was to address publication bias [7]. There
is reason to believe that this problem may be relevant and
prevalent in the context of decision models [8, 9]. Many
submissions to health technology assessment (HTA)
agencies are never formally published [10]. There is no
easy way to identify previously conducted modelling
studies or those currently underway. Evidence suggests that
there is significant bias in the conduct and reporting of
cost-effectiveness studies [11]. Even where studies are
published, reporting standards can be poor and models
often constitute a black box [12].
Model transparency is an issue that has been given much
consideration, perhaps most notably by the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) and Society for Medical Decision Making
(SMDM) Modeling Good Research Practices Task Force
[13], yet there are few signs of improvement in practice.
The traditional infrastructure of scholarly publishing does
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not provide an adequate means by which to ensure trans-
parency. Peer reviewers usually do not have sight of the
files underpinning a decision model and may be unable to
identify sources of bias. Some journals, including Phar-
macoEconomics—Open, encourage models to be included
as supplementary material. The majority of journals do not,
and there are none that mandate it. Thus, most editors, peer
reviewers and readers can do little more than assume good
faith.
As some publishers adopt more progressive arrange-
ments for the availability of data and analysis files, there
remains inconsistency in the way journals oversee the
publication of supplementary materials [14]. Online
appendices are not indexed and usually reside behind
paywalls. There is little scope for versioning that would
allow for updates or revisions.
Reports of model-based studies often lack details of any
attempts at either internal or external validation (e.g.
[15–17]). Even where model developers do report on val-
idation, it is vital that decision makers and other model
users are themselves able to assess model validity [18].
Restricted access to underlying data and analysis files
means that this is rarely possible. A lack of transparency in
modelling—in terms of study availability and reporting
standards—may contribute to a lack of validation. Trans-
parency and validation are co-dependent and together
allow users to assess the credibility of a model.
There may always be intentionally misleading models,
with which regulators will have to deal. However, most
models that suffer from validity issues will do so in spite of
researchers’ best intentions. At present, researchers have
few incentives to share full details of their models and any
validation attempts. Modellers working for manufacturers
and consultancies may have strong incentives to maintain
secrecy around their models in order to protect intellectual
property, pricing information or other business interests.
2 The Solution
We propose the creation of a registry and linked database
of model-based economic evaluations. Despite previous
calls to establish a model registry [2, 19], there are no signs
that any organisation is moving to do so. This may in part
be due to the lack of a clear proposition for the initiation of
a registry. We see the following steps as a means of con-
structing a sustainable registry from the bottom up, with
minimal resources.
2.1 Formation of a Task Force
A small group of volunteers will probably be needed to
drive the creation of the registry and follow through with
the subsequent steps outlined here. Ideally, modellers from
both academia and industry would be involved. The group
should start by establishing a set of policies. Minimum
requirements for inclusion in the registry would need to be
determined. These could correspond to the non-technical
documentation items described by the ISPOR-SMDM Task
Force [13]. Standards for designation and classification of
models and a system of record identification and number-
ing must also be determined.
2.2 Creation of a Website
Each entry into the registry should have a corresponding
webpage including information about the model, its ver-
sioning, its creators and any associated publications. The
task force should develop a template that satisfies the
standards and policies previously determined. It is vital that
the registry supports linked versioning to provide trans-
parency around the development of a model. The website
should be built on the tenets of openness and collaboration.
To this end, the website could be created using wiki soft-
ware or elicit contributions via webforms. The content of
the website itself should be provided under a Creative
Commons Licence. Crucially, the website should facilitate
discussion to encourage peer review.
2.3 Proactive Retrospective Registration
Once a website has been created, the priority for the reg-
istry will be to gather as many entries as possible. This will
prompt a phase of learning and adjustment as a variety of
model types and sources are identified. It may be necessary
to revise policies accordingly. In the first instance, models
should be identified by the task force through literature
review. Every version of every unique decision model
should be entered into the registry. Ideally, modellers
would enter their own models, but other volunteers will be
needed. Ultimately, the registry should be complemented
by a database of supporting files. These files should include
technical and non-technical documentation, citations,
manuals and code. However, the development of a data-
base will be costly. Therefore, in the initial phase, the
registry should be supported by a decentralised biblio-
graphic database. Existing services such as Figshare [20],
Zenodo [21] and Open Science Framework [22] can be
used to collect currently available modelling files. Springer
Nature recently partnered with Figshare to provide bespoke
data repositories for journals [23]. The registry should link
to relevant files published online as supporting material by
journals, in data repositories or on researchers’ own
websites.
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2.4 Stakeholder Engagement
The principal challenge for the success of the registry will
be in encouraging researchers to prospectively register
models and provide supporting files and information for
those already published. It is, therefore, vital that the task
force engages with researchers across sectors. As is the
case for clinical trial registration, researchers could be
incentivised to register their models by journal editors
making registration a prerequisite to manuscript consider-
ation. Registration could become a funding requirement for
those conducting publicly funded research, or mandated by
HTA agencies for appraisal submissions. The task force
should strive to make arrangements with, and gain public
support from, publishers and funders. In preparation for the
second phase development outlined below, the task force
should engage with relevant scholarly societies and other
stakeholder organisations.
2.5 Second Phase Development
There will be costs associated with maintaining a registry
and database [2], and it will be necessary to establish the
financial capacity to pay for required support services. The
second phase of development must focus on sustainability.
There are a variety of possibilities for the long-term
development of a registry. As is the case for clinical trial
registration, a competitive market of registry providers
could develop. Alternatively, a single organisation may
seek to adopt the project or the task force may wish to seek
financial support and establish a new organisation to ensure
the sustainability of the registry. Creating the registry
collaboratively and in the public domain, as described
above, will ensure that all of these pathways remain open.
The priority will be to secure the means of sustainable
preservation of the registry. Each entry in the registry (i.e.
each version of each model) should be associated with a
digital object identifier (DOI). The creation of a centralised
database may also be worthwhile. The database could be
developed in order to satisfy funders’ and journals’ existing
data sharing policies, such as that of PharmacoEco-
nomics—Open, which encourages data and analysis files to
be deposited in a public repository and made available to
all researchers.
3 The Benefits
By mandating registration of models, research funders and
technology assessment agencies could bring an end to
publication bias. Even if models are not subsequently
described in academic journals, their being recorded in the
registry would provide a fuller understanding of the
evidence base. The registry would also facilitate feedback
and discussion, forming the basis for pre- and post-publi-
cation peer review. It could also stimulate collaborative
validation efforts.
A model registry would help guarantee intellectual
property. Plagiarism or use of models without appropriate
attribution could easily be recognised and acted upon. A
registry could become the basis for academic competition
by creating incentives for researchers to provide more
information about their models in order to increase their
citability. The registry would facilitate citation of models,
rather than journal articles based on models, allowing
credit to be given more appropriately. Financial interests
need not be undermined by inclusion in the registry.
Indeed, licensing information could be included within the
registry and used as a basis for attracting consultancy or
other forms of income.
The registry could be consulted before work was com-
missioned, and could inform funding applications. This
would help prevent duplication of efforts and waste of
research resources. The registry itself could become the
subject of research, as have other registry and database
projects such as the Tufts Medical Center CEA Registry
[24]. Evidence gaps could be recognised and the genealogy
of models and broad methodological trends identified. In
this way, the registry would also contribute to method-
ological development, as model structures move beyond
traditionally recognised taxonomies [25, 26]. This could be
valuable to disciplines outside of health economics.
4 Closing Remarks
There are reasons to be hopeful. A growing number of
registries and databases have been established in our field,
such as DIRUM [27], CEA Registry [24], ScHARR HUD
[28] and a database of mapping studies [29]. Recent years
have seen interjournal agreement [30] and co-publication
of guidelines [31, 32]. Some researchers have gone to great
lengths to test the validity of models, signalling appetite for
a more concerted effort. The Mt Hood Challenge is a prime
example of collaborative validation [33]. Moreover, pre-
liminary research has signalled a desire for open-source
models [34].
An open and transparent registry would enable fuller
assessment of the validity of models, which may be used to
inform policy decisions with direct implications for peo-
ple’s health and well-being. A registry could also help
prevent waste of research resources, which is itself an
ethical concern. We call on publishers, research funders,
HTA agencies and most importantly researchers them-
selves to move to establish a model registry.
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